Luye Pharma Group Ltd.
LYPHF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $9,436,518 | $11,330,752 | $18,006,103 | $16,414,293 |
| - Cash | $4,937,145 | $3,238,973 | $2,323,740 | $2,438,252 |
| + Debt | $10,321,054 | $8,423,947 | $9,104,519 | $9,490,793 |
| Enterprise Value | $14,820,427 | $16,515,726 | $24,786,882 | $23,466,834 |
| Revenue | $6,061,441 | $6,143,078 | $5,981,656 | $5,200,226 |
| % Growth | -1.3% | 2.7% | 15% | – |
| Gross Profit | $4,044,227 | $4,204,175 | $4,140,516 | $3,396,740 |
| % Margin | 66.7% | 68.4% | 69.2% | 65.3% |
| EBITDA | $2,191,676 | $2,077,405 | $1,812,830 | $906,883 |
| % Margin | 36.2% | 33.8% | 30.3% | 17.4% |
| Net Income | $471,886 | $532,605 | $604,807 | -$144,783 |
| % Margin | 7.8% | 8.7% | 10.1% | -2.8% |
| EPS Diluted | 0.018 | 0.14 | 0.17 | -0.042 |
| % Growth | -87.5% | -17.6% | 504.8% | – |
| Operating Cash Flow | $167,764 | $1,595,487 | $1,653,796 | $182,371 |
| Capital Expenditures | -$1,708,497 | -$1,165,261 | -$1,163,659 | -$1,541,595 |
| Free Cash Flow | -$1,540,733 | $430,226 | $490,137 | -$1,359,224 |